REFERENCES

1. NAMSE. National action league for people with rare diseases. Available from: https://www.namse.de/english [Last accessed on 23 May 2022].

2. Haase J, Wagner TOF, Storf H. [se-atlas - the health service information platform for people with rare diseases : Supporting research on medical care institutions and support groups]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2017;60:503-9.

3. Medical Informatics Initiative. About the initiative. Available from: https://www.medizininformatik-initiative.de/index.php/en/about-initiative [Last accessed on 23 May 2022].

4. Institute - Fraunhofer ITMP. Fraunhofer institute for translational medicine and pharmacology ITMP. Available from: https://www.itmp.fraunhofer.de/en/institute.html [Last accessed on 23 May 2022].

5. Fraunhofer-Annual-Report-2019. Available from: https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/2019/Fraunhofer-Annual-Report-2019.pdf [Last accessed on 23 May 2022].

6. Pages - Our ISCIII Centres. Available from: https://eng.isciii.es/eng.isciii.es/QuienesSomos/CentrosPropios/Paginas/default.html [Last accessed on 23 May 2022].

7. NHS commissioning. Highly specialised services. Available from: https://www.england.nhs.uk/commissioning/spec-services/highly-spec-services/ [Last accessed on 23 May 2022].

8. Our Centres. The catapult network. Available from: https://catapult.org.uk/about-us/our-centres/ [Last accessed on 23 May 2022].

9. Cell and Gene Therapy Catapult - Annual Reviews. Available from: https://ct.catapult.org.uk/our-impact/annual-reviews [Last accessed on 23 May 2022].

10. Construction completed on CGT Catapult expansion. Available from: https://ct.catapult.org.uk/news-media/manufacturing-news/construction-completed-expansion-phase-doubling-capacity [Last accessed on 23 May 2022].

11. Genome Canada. Genome Canada’s role. Available from: https://www.genomecanada.ca/en/why-genomics/genome-canadas-role [Last accessed on 23 May 2022].

12. Indigenous Health. The silent genomes project. Available from: https://www.indigenoushealthnh.ca/news/silent-genomes-project-indigenous-DNA [Last accessed on 23 May 2022].

13. Rare diseases: models & mechanisms network. Available from: http://www.rare-diseases-catalyst-network.ca/about-the-network.html [Last accessed on 17 Jan 2022].

14. CARE for RARE. Available from: http://care4rare.ca [Last accessed on 17 Jan 2022].

15. Buske OJ, Girdea M, Dumitriu S, et al. PhenomeCentral: a portal for phenotypic and genotypic matchmaking of patients with rare genetic diseases. Hum Mutat 2015;36:931-40.

16. Ontario genomics. What we do. Available from: https://www.ontariogenomics.ca/about-us/what-we-do/ [Last accessed on 23 May 2022].

17. CORD. Now is the time: a strategy for rare diseases is a strategy for all Canadians. Available from: http://www.raredisorders.ca/content/uploads/CORD_Canada_RD_Strategy_22May15.pdf [Last accessed on 23 May 2022].

18. Government of Canada. National strategy for drugs for rare diseases online engagement. Available from: https://www.canada.ca/en/health-canada/programs/consultation-national-strategy-high-cost-drugs-rare-diseases-online-engagement.html [Last accessed on 23 May 2022].

19. FDA. Developing Products for Rare Diseases & Conditions. Available from: https://www.fda.gov/industry/developing-products-rare-diseases-conditions [Last accessed on 17 Jan 2022].

20. Congressional Research Service. National institutes of health (NIH) funding: FY1996-FY2023. Available from: https://sgp.fas.org/crs/misc/R43341.pdf [Last accessed on 23 May 2022].

21. GARD. Office of Rare Diseases Research (ORDR) Brochure - Office of Rare Diseases Research. Available from: https://rarediseases.info.nih.gov/asp/resources/ord_brochure.html [Last accessed on 23 May 2022].

22. Rare Diseases Clinical Research Network. Available from: https://www.rarediseasesnetwork.org/ [Last accessed on 23 May 2022].

23. National Center for Advancing Translational Sciences. Rare diseases clinical research network (RDCRN). Available from: https://ncats.nih.gov/rdcrn [Last accessed on 23 May 2022].

24. National Center for Advancing Translational Sciences. Therapeutics for rare and neglected diseases (TRND). Available from: https://ncats.nih.gov/trnd [Last accessed on 18 Jan 2022].

25. Genetic and Rare Diseases Information Center (GARD) - an NCATS Program. Available from: https://rarediseases.info.nih.gov/ [Last accessed on 23 May 2022].

26. National center for advancing translational sciences. Rare diseases registry program (RaDaR). Available from: https://ncats.nih.gov/radar [Last accessed on 23 May 2022].

27. UDN. Undiagnosed diseases network. Available from: https://undiagnosed.hms.harvard.edu/ [Last accessed on 23 May 2022].

28. Ito T. Patient groups’ advocacy activity and nanbyo act (The Iatric Services to Patients Suffering from Intractable Disease): from the view point of patient groups. Journal of Health Care and Society 2018;28:27-36.

29. Richter T, Nestler-Parr S, Babela R, et al. International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest Group. Rare disease terminology and definitions-a systematic global review: report of the ISPOR rare disease special interest group. Value Health 2015;18:906-14.

30. Japan Agency for Medical Research and Development. Practical research project for rare / intractable diseases. Available from: https://www.amed.go.jp/en/program/list/11/02/003.html [Last accessed on 23 May 2022].

31. Adachi T, Kawamura K, Furusawa Y, et al. Japan’s initiative on rare and undiagnosed diseases (IRUD): towards an end to the diagnostic odyssey. Eur J Hum Genet 2017;25:1025-8.

32. RADDAR-J. RADDAR-J - Rare Disease Data Registry of Japan. Available from: https://www.raddarj.org/en/ [Last accessed on 18 Jan 2022].

33. IRDiRC. Automatable discovery and access. Available from: https://irdirc.org/activities/task-forces/automatable-discovery-and-access/ [Last accessed on 18 Jan 2022].

34. About OPIR. Office of pharmaceutical industry research. Available from: https://www.jpma.or.jp/opir/en/about/index.html [Last accessed on 18 Jan 2022].